Zelira Therapeutics - Global Leader in cannabinoid-based medicine

Zelira Therapeutics Ltd is a leading global cannabinoid-based biopharmaceutical company with access to the world’s largest and fastest growing markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. The Company is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.
Patient

We’re here to help you access alternative treatment options

Patients
Doctors + Specialists

Supporting healthcare professionals and patients with cannabinoid-based medicines

Doctors + Specialists
Pharmacists

Supporting healthcare professionals and patients with cannabinoid-based medicines

Pharmacists

Recent Video and Audio from Zelira Therapeutics

Investor Webinar – Update on Zelira’s progress with the FDA pre-IND meeting and HOPE SPV
November 19, 2025
Zelira Therapeutics FY25 AGM Presentation

Chairman Mr. Osagie Imasogie and Global CEO Dr. Oludare Odumosu provide an update on 2025 milestones and the outlook for Zelira Therapeutics.

September 20, 2024
Investor Webinar – Update on Zelira’s progress with the FDA pre-IND meeting and HOPE SPV

Chairman Mr Osagie Imasogie and Global CEO Dr Oludare Odumosu provide investors with an update on the recent progress with the FDA pre-IND meeting and next steps for the HOPE SPV. The formal presentation is followed by a Q&A session.

June 1, 2023
Investor Webinar: Top line trial results of Zelira’s diabetic nerve pain drug vs Lyrica®

Osagie Imasogie (Chairman) and Oludare Odumosu (Global CEO) take investors and analysts through the top line comparative trial results of Zelira’s diabetic nerve pain drug vs Lyrica® including efficacy, safety and next steps for the organisation.

February 22, 2023
Investor Webinar: HOPE® 1 SPV created to fund Ph.2 and Ph.3 US FDA trials

Chairman Osagie Imasogie and CEO Oludare Odumosu lead a presentation on the creation of an SPV and US $8.6M cornerstone funding from Cantheon Capital LLC for HOPE 1 Ph.2 and Ph.3 US FDA clinical trials.

November 17, 2022
Zelira AGM Presentation 2022

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Oludare Odumosu present a company update at the 2022 Annual General Meeting.

November 15, 2022
Zelira CEO Oludare Odumosu speaks with Proactive

Zelira Global CEO Oludare Odumosu provides Proactive with an update on the company’s progress with its proprietary revenue-generating products, global expansion and its pipeline of candidates undergoing clinical development.

Contact Us

    Follow Zelira Therapeutics

    Subscribe

      Zelira Therapeutics
      Level 3, 101 St Georges Terrace, Perth WA 6000
      Phone +61 8 6558 0886

      Copyright © Zelira Therapeutics. All rights reserved. | Disclaimer.

      Start typing and press Enter to search

      View more
      Shopping Cart